European Approval for Pfizer-Wyeth Deal
20 July 2009
Pfizer's pending acquisition of Wyeth has been approved by the European Commission.
However, despite this step forward, final completion of the deal still remains subject to a number of factors; expiration of the waiting period under the US Hart-Scott-Rodino Antitrust Improvements Act, various other governmental and regulatory approvals and, perhaps most importantly, approval by Wyeth stockholders.
In a press release, Amy Schulman, senior vice president and general counsel at Pfizer said: "We are pleased to have achieved another significant milestone for the pending acquisition with the EC's approval of the transaction."
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
